Product Images Alendronate Sodium

Not available.*

This is a graph representing the cumulative incidence percentage of hip fractures over a three-year study of FIT in patients with radiographic vertebral fractures at baseline. The graph compares the placebo group to the group treated with Alendronate Sodium over time in months.*

This text appears to be a table showing the results of osteoporosis treatment studies in postmenopausal women. The table shows the increase in BMD (bone mineral density) after three years of taking Alendronate Sodium at a dosage of 10 mg/day. The results are displayed for the Lumbar Spine, Femoral Neck, and Trochanter. There are also some numbers in the table, possibly related to the study participants, but it is difficult to interpret without more context.*

This appears to be a table of results from a study on the change in bone mineral density (BMD) in postmenopausal women. The table shows the mean percentage change in BMD from baseline after 2 and 3 years of the study. The BMD measurements were taken at various sites in the body, including the lumbar spine, femoral neck, and trochanter. There is also information about the amount of sodium intake in the study participants.*

This is a study on Paget's disease of bone where the effect of Alendronate Sodium 40 mg/day on serum alkaline phosphatase levels was compared to placebo or Etidronate 400 mg/day. The study had a total of 27 participants, and the results were reported as mean percent change from baseline serum levels. The data were presented in a graph showing the change in serum levels over time in months.*

This is a drug label for Alendronate Sodium tablets that are to be taken once a week. The label includes dosage information, instructions on how to remove tablets, and storage information. The drug is prescribed for the treatment of osteoporosis.*